Working… Menu

Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00246675
Recruitment Status : Withdrawn (The study has ceased recruiting as Ethics approval has lapsed and the investigator availability reduced.)
First Posted : October 30, 2005
Last Update Posted : April 27, 2015
Information provided by:
Melbourne Health

Brief Summary:
The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.

Condition or disease Intervention/treatment Phase
Renal Impairment After Cardiac Surgery Drug: Frusemide Not Applicable

Detailed Description:

All patients will receive standard supportive care based on current established management practice of cardio-thoracic patients. The only difference in treatment will be the randomisation of patients to receive/not receive protocolised administration of frusemide targeting a urine output.

There will be 2 groups of patients. The control group-which will receive frusemide bolus doses if required as determined by the surgeon/consultant physician. The frusemide infusion group-which will be monitored to achieve a trial specified hourly urine output target range of 1-2mls/kg/hour. In order to achieve this target the patient may need to receive a loading dose of frusemide and may also then require a frusemide infusion. The aim will be to maintain the urine output within the target range for the first 48 hours after cardiac surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Frusemide Infusion for the Prevention of Deterioration of Renal Function in Post Cardiac Surgery

Resource links provided by the National Library of Medicine

Drug Information available for: Furosemide

Arm Intervention/treatment
Standard Care
Patients will only receive frusemide as per the treating physicians treatment
Drug: Frusemide
Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
Drug: Frusemide

Primary Outcome Measures :
  1. The incidence of increase in creatinine of 0.05 mmol/L or greater in the first 72 hours after cardiac surgery.

Secondary Outcome Measures :
  1. 1. The maximum change in serum creatinine from baseline value during the first 7 days of hospital stay.
  2. 2. Incidence of renal failure requiring any form of renal replacement therapy.
  3. 3. Duration of post-operative hospital and ICU stay.
  4. 4. The maximum Sequential Organ Failure Assessment (SOFA) score in the first 7 days of hospital stay.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

All patients admitted for cardiac surgery will be assessed for eligibility. Participants will be approached for inclusion, from the pre-admission clinics and wards of the Cardiothoracic surgery unit. Potential participants will be identified by the daily review of planned cardiothoracic surgery schedule.

Exclusion Criteria:

  1. Already in established dialysis dependent chronic renal failure.
  2. Known allergy to frusemide
  3. Age < 18 years
  4. Pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00246675

Layout table for location information
Australia, Victoria
Intensive Care Unit, Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Sponsors and Collaborators
Melbourne Health
Layout table for investigator information
Principal Investigator: John F Cade Royal Melbourne Hospital, Intensive Care Unit
Layout table for additonal information Identifier: NCT00246675    
Other Study ID Numbers: 2002.167
First Posted: October 30, 2005    Key Record Dates
Last Update Posted: April 27, 2015
Last Verified: April 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action